Beyond Air, Inc.

Beyond Air, Inc.

NNASDAQ:XAIR
2.02
USD
-0.11
(-5.16%)
-64.49EPS
6.63MMarket Cap
Feb 11Next Earn

Q3 FY2026 · Earnings Call TranscriptFebruary 13, 2026

Operator

Good morning, and welcome everyone to the Beyond Air financial results call for the fiscal quarter ended December 31st, 2025. At this time, all participants are in listen-only mode.

A question-and-answer session will follow the formal presentation. Now, I'd like to turn the call over to Corey Davis of LifeSci Advisors.

Please go ahead.

Corey Davis

Thank you, operator. Good morning, everyone, and thank you for joining us.

Earlier today, we issued a press release announcing the operational highlights and financial results for Beyond Air's third quarter of fiscal 2026 ended December 31st, 2025. A copy of this press release can be found on our website, beyondair.net, under the News and Events section.

Before we begin, I would like to remind everyone that we will be making comments and various remarks about future expectations, plans, and prospects, which constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Beyond Air cautions that these forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those indicated.

We encourage everyone to review the company's filings with the Securities and Exchange Commission, including, without limitation, the company's most recent Form 10-K and Form 10-Q, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements. Additionally, this conference call is being recorded and will be available for audio rebroadcast on our website, beyondair.net.

Furthermore, the content of this conference call contains time-sensitive information that is accurate only as of the date of the live broadcast, February 13th, 2026. Beyond Air undertakes no obligation to revise or update any statements to reflect events or circumstances after the date of this call.

With that, I'll turn the call over to Steve Lisi, Chief Executive Officer of Beyond Air. Steve, go ahead.

Steve Lisi

Thanks, Corey, and good morning to everyone. With me here today is Dan Moorhead, our new Chief Financial Officer.

It has been a pleasure working with Dan over the past several months. He brings a proven track record as a proactive CFO with demonstrated success supporting commercial organizations through periods of rapid growth.

I also look forward to his active engagement with the investment community as he becomes fully integrated into the role. Also joining us today is Bob Goodman, our Chief Commercial Officer.

Bob assumed the role in October after previously joining Beyond Air as a board member back in June. Let me start my prepared remarks by saying just how pleased I am to speak with you today and provide an update on what has been a productive and meaningful period for our company.

We have achieved several significant milestones, strengthened our balance sheet to support continued commercial execution, and made a strategic decision to sell our neuronOS subsidiary in exchange for equity in the acquiring company and up to $32.5 million in upfront, development, and commercial milestone payments. We believe these recent events have strengthened our ability to execute our commercial strategy and create long-term value for our shareholders.

Let me walk you through these updates in greater detail. Starting with our core business, revenue in the fiscal quarter increased 105% year-over-year to $2.2 million.

This represents continued progress as we scale adoption and expand awareness of LungFit PH in clinical settings. We now support more than 45 hospitals across the United States and internationally that have adopted our first-generation LungFit PH system.

Customer feedback has been encouraging, with retention exceeding 90% and more than half of customers under multi-year agreements. We believe this installed base positions us well to support continued revenue growth from our first-generation system while preparing for the anticipated FDA decision for our second-generation system.

Our commercial team continues to refine its targeting strategy, prioritizing hospitals most likely to adopt LungFit PH today, and expand usage following approval of the second-generation system, which we expect to receive before the end of calendar 2026, subject to regulatory review and clearance. We are making steady progress building relationships with clinicians, administrators, and healthcare systems.

Our current objective is to continue expanding Gen 1 system utilization through calendar 2026 in the US and internationally, while preparing for the potential launch of our second-generation system once approved. As previously discussed, Gen 2 system is designed to offer reduced size and weight, simplified operation, extended service intervals, improved backup system functionality, and very importantly, compatibility with both air and ground transport.

We believe these enhancements will expand the addressable market relative to Gen 1 and support broader adoption over time. At this point, I'm going to pass the call over to Bob Goodman, who has made excellent progress since taking the reins as Chief Commercial Officer about four months ago.

Bob?

Bob Goodman

Thanks, Steve. Let me begin by saying I share Steve's enthusiasm about the opportunities ahead for Beyond Air.

I, as well, believe that LungFit PH is the best-in-class nitric oxide solution globally. Feedback from US customers and international partners on system performance and customer support have been extremely positive, providing a solid foundation for continuous growth.

We have national group purchasing organization agreements with Premier and Vizient, which together provide access to nearly 3,000 hospitals across the United States. As awareness of LungFit PH increases, we expect additional opportunities at the GPO and integrated delivery network level in 2026.

As previously announced, we have been working with Trillamed to support our engagements with the federal healthcare systems. I'm pleased to announce that together with this valued partner, we completed the first sale of LungFit PH to a VA medical center.

This initial commercial sale to the VA hospital system establishes an important foothold, opening potential pathways for future orders and broader adoption across the system that provides access to the largest healthcare network in the United States. Internationally, we continue to see strong engagement from our distribution partners.

Over the past several months, we've expanded our global LungFit PH distribution network with new agreements in Canada, Germany, Brazil, Austria, the Netherlands, and Sri Lanka, bringing total international coverage to 40 countries. As we broaden our global footprint, we are laying the groundwork for long-term growth and positioning Beyond Air to serve a significantly larger addressable market.

It is important to note that we are live in a few hospitals with LungFit PH and have already begun to see repeat orders for accessories from several countries. Taken together, these commercial, operational, and strategic developments give me confidence in the trajectory of the business.

What also gives me confidence are the people of Beyond Air. The dedication of this team is second to none that I've been in this business for decades.

This includes all the aspects of the team, from clinical support, to marketing, to customer service, to engineering, to finance, to regulatory, to quality, etc. Our people are fully engaged and dedicated to the vision of improving the lives of patients and medical staff with LungFit PH.

I also want to emphasize the advantages that Steve mentioned earlier on our second-generation system. From my time spent with customers and potential customers in the United States, I believe that the Gen 2 system addresses everything on the wish list from clinicians and hospitals.

I'm extremely confident that I, along with the team here, will execute on our vision of becoming the global nitric oxide leader. Now I'll turn things back over to Steve.

Steve Lisi

Thanks, Bob. Turning to Beyond Cancer, we recently announced that our abstract was selected for the 2026 AACR Annual Meeting, which is taking place from April 17th to 22nd in San Diego, California.

As previously announced, the study enrolled 10 subjects at doses of 25,000 and 50,000 parts per million of nitric oxide gas delivered over five minutes intratumorally. These patients all had metastatic disease and were heavily pre-treated.

All subjects had a life expectancy of less than 12 months. We have already reported that the safety profile observed to date is acceptable.

The data to be presented at AACR will include updated overall survival data for which median survival has not yet been reached as of October 1st, 2025. We remain dedicated to pursuing the Phase 1b combination study with anti-PD-1 therapy, and we will communicate more details as we progress.

With respect to neuronOS, our neurology-focused subsidiary, on January 13th, 2026, XTL Biopharmaceuticals announced a binding letter of intent to acquire neuronOS. In exchange for Beyond Air's approximately 85% ownership interest, consideration includes a 19.9% stake in XTL, $1 million in cash, and milestone-based contingent payments totaling up to $31.5 million.

Following closing, neuronOS is expected to serve as XTL's flagship platform for autism and neuro-oncology development. We believe this agreement provides the potential to create meaningful value for our shareholders by enabling neuronOS's pipeline to advance with dedicated focus and funding through XTL Bio.

We will not provide additional commentary beyond public disclosures while the transaction remains pending. To conclude, the $5 million financing completed in January 2026, together with the previously announced promissory note and equity line of credit for up to $32 million with Streeterville Capital that we announced in November 2025, provide resources to support commercial execution and readiness for the second-generation LungFit PH system.

We remain focused on disciplined execution and delivering advanced nitric oxide solutions to clinicians and patients around the world. Now I will turn it over to our CFO, Dan Moorhead.

Dan Moorhead

Thanks, Steve. Good morning, everyone.

I'm excited to join my first call since being appointed CFO about seven weeks ago. I still have a lot to learn, but I'm incredibly impressed by what the team has achieved, not just over the past year, but even within the past few months.

The progress has been extraordinary, and I see a bright future ahead as the team continues to execute on our growth strategy. Our financial results for the third quarter of fiscal year 2026, which ended December 31st, 2025, are as follows.

Revenue for the fiscal quarter ended December 31st, 2025 increased 105% to $2.2 million, compared with $1.1 million for the fiscal quarter ended December 31st, 2024. On a sequential basis, this represents a 21% increase compared with last quarter.

Gross profit increased to $300,000 for fiscal third quarter 2026, compared to a gross loss of $200,000 for the same period last year, and a gross loss of $300,000 in the prior quarter. Turning to operating expenses, we continue to see reductions across SG&A, R&D, and in our supply chain as a result of cost reduction initiatives taken in the past 12 months, as well as the decrease in R&D costs related to our Gen 2 device, which are mostly behind us since the PMA was filed with the FDA.

Total operating expenses for the fiscal third quarter of 2026 were reduced to approximately $6.9 million, which is down from $10.7 million for the same period last year. This translates to a 36% reduction year-over-year, and a greater than 60% reduction from the high of $17 million at its peak.

Research and development expenses were $2.4 million for fiscal third quarter of 2026, as compared to $3 million for the same period last year. As I mentioned earlier, the year-over-year decrease was primarily driven by lower development costs associated with our Gen 2 device, with the remaining reduction attributable to a decrease in headcount and related costs.

SG&A expenses for the quarters ended December 31st, 2025 and December 31st, 2024 were $4.5 million and $7.7 million, respectively, a decrease of 42% year-over-year. Almost all of the decrease of $3.3 million was from a reduction in employee-related costs.

Other expense was $1 million, compared to $2.4 million for the same period a year ago. The decrease in expense of $1.5 million was primarily attributed to the prior period loss associated with the extinguishment of debt of $1.9 million.

Net loss attributed to common stockholders of Beyond Air was $7.3 million, or a loss of 85 cents per share, basic and diluted, compared with $13 million, or a loss of $2.96 per share, basic and diluted. Please note that the per-share results for both periods were calculated to reflect the company's 1-for-20 reverse stock split, which became effective on July 14th, 2025.

Net cash burn for the quarter was $4.3 million, which is a reduction of over 40% versus a year ago. We believe our overall cash burn will continue to reduce as revenue grows, and will only get better until we get approval and start building inventory in preparation for the launch of Gen 2.

As of December 31st, 2025, we reported cash, cash equivalents, restricted cash, and marketable securities of $17.8 million. Subsequent to the end of the third quarter, we completed a $4.5 million equity financing, net of issuance costs, and we believe this capital provides us with a cash runway into calendar year 2027, and potentially to profitability, provided we continue to hit our current revenue estimates and continue to control costs.

With that, I'll hand the call back to Steve.

Steve Lisi

Thanks, Dan. Operator, we'll take questions now.

Operator

Thank you. At this time, if you'd like to ask a question, please press *1 from your telephone keypad, and a confirmation tone will indicate your line is in the question queue.

You may press *2 if you'd like to withdraw your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys.

One moment, please, while we poll for our first question. Thank you.

The first question comes from the line of Mike King with Rodman & Renshaw. Please proceed with your questions.

Mike King

Thanks for taking the question. Good morning, guys.

I have a couple of questions, if you don't mind. I just wonder if you could talk a little bit more about the sales process.

I think it's a great breakthrough that you got sales into the VA system, our VA hospital, I should say. It brings up the topic of the VA system, as you mentioned.

How do you penetrate systems rather than a single hospital at a time? What needs to happen in terms of the sales process or the RFPs or things like that that can see us knocking off more than one healthcare facility at a time?

Steve Lisi

Mike. Thanks for the question.

Go ahead, Bob. You take this one.

Bob Goodman

Sure. Then you can definitely provide any color you'd like, Steve.

Thank you. Mike, with the VA system, where we're on and our product is being offered through the ECAT system.

That catalog actually makes it an easier approach for our customers to get to us directly. It's outside of an RFP process.

We're still able to actually compete with other RFPs that come out through, there's a couple of different ways that the VAs contract with vendors. Yeah.

We have access that way, it's great.

Mike King

Okay. In your formal comments, you mentioned words to the effect that you're identifying facilities most likely to acquire the system.

Or can you say how you identify them and maybe help us understand how you're targeting those facilities?

Bob Goodman

Yeah. We've done a really good job standing up our commercial organization both in the US and internationally.

Right now what we're doing is we're focusing, not to say an overhaul, but more of an exactness with our people and our process and our technology. Different prospecting tools with good intelligence and good CRM rigor to follow up with the customers, and taking the process of real good demand generation, where we're getting top of the funnel looks at our customers, and having really good pipeline discipline, we could get in front of the right customers.

Then have our people, the people part of it in the right places at the right time, with the right coverage, we have that right reach and frequency getting in front of these customers and just getting in front of more and more, we have that touch. We've been really refining that.

The customers are really responding well for our ability to get in front of them.

Mike King

That's great. Has there been any appreciable change in length of the sales cycle?

Bob Goodman

That pretty much, Mike, still remains the same. At the real front end, if you get kind of real lucky based off of the timing of a contract that might be expiring, and that customer is really, really organized and you can knock out a real quick demo and evaluation, you can do that in that four- or five-month timeframe.

It's really in that right around six to nine months, and it could be longer. What we're doing is a good job identifying the customers, and again, reaching out to them and finding out where they're at with their contract, and making sure that they see the value of our product.

With that, we're hoping that that might restrict things just a bit. We're really organized, and our clinical teams are out there in the field with our sales teams to make sure that we're in front of them as early as possible.

Mike King

Okay. I apologize, just one more quick one.

How do you segment, or can you segment the next-gen system? Is this typical of a lot of businesses where a next-generation chip, let's say, is coming out, or something, and that the sales cycle kind of concertina effect, where the purchaser may hold off until the next-gen system is available?

Is that a concern, or are you segmenting a different market with the new system? Thank you.

Bob Goodman

We're focusing right now, as you'd expect, on our first-generation product, and it's been really well received, the version 24 of Gen 1. We're focusing on the non-transport systems, okay?

We're being really well received there. As there's natural conversations within the market for the transportation systems, that's a later on Gen 2 conversation, and we're really kind of breaking away from those conversations, but being aware that these are systems that are going to want to be working with us in the future.

Mike King

Okay. All right.

Thanks for indulging me, guys.

Bob Goodman

You got it.

Steve Lisi

Thanks, Mike.

Operator

The next question is from the line of Marie Thibault with BTIG. Please proceed with your questions.

Marie Thibault

Good morning. Thanks for taking the questions, and welcome, Bob and Dan.

Wanted to quickly just check in on any communications you've been having with the FDA on the Gen 2 process, just speak to your confidence in the timeline. I think you've said by end of calendar year.

Then what will be needed to do post-clearance in terms of building inventory, kind of a timeline we might think about before you can go in the formal launch and ramp?

Steve Lisi

Okay. Thanks, Marie.

I'll comment on the FDA side. We've been having fairly constant communication with FDA, and we're very happy with the interaction.

We don't really see any major hurdles. Everything that FDA has asked for, we'll provide them.

Shouldn't be a problem. I'm sure the process will continue with FDA, and we'll continue to answer the questions as we go forward.

We still are waiting on the work to be completed with our contract manufacturer so we can be inspected. That's essentially, in our minds, what the gating factor will be from a timing perspective.

We feel highly confident in the timelines that we've provided, given the state of affairs today. I don't know if that gave you the answers you needed,

Marie Thibault

or

Steve Lisi

if there's other things you want to ask.

Marie Thibault

All right. That's great to hear.

Thank you for that, Steve. Then I guess I'll ask a quick follow-up here on the international side.

I know you've got some great partnerships and some efforts going on there. Any wins or any catalysts to think about on the international side?

Thanks for taking the questions.

Steve Lisi

Sure. Bob, you want to take the international question?

Bob Goodman

Sure. We have had some recent wins, which is great.

I think, as you know from the past calls, it was all about setting up and getting our distributors armed with our demo devices so they can get in front of the systems. Then there's the whole part of the process with whether it's Europe or Middle East or Australia, where it's mostly tenders, compared to the UK or Portugal, where there's a national framework, or you get that hunting license like Germany and APAC, where you can go direct.

With all those different regions, yeah, no, we've had wins. On top of having wins, we're now actually seeing customers reorder filters.

The product is being deployed into hospitals now, which is great. We're starting to again, get that stickiness, it's fantastic.

Marie Thibault

All right. Thank you so much.

Bob Goodman

Yeah.

Steve Lisi

Thanks, Marie.

Operator

Our next question is from the line of Justin Walsh with Jones Trading. Please proceed with your questions.

Justin Walsh

Hi, thanks for taking the question. Wondering if you can provide any color on what attracted XTL Biopharmaceuticals to be interested in the neuronOS opportunity, and then how I guess collaboration or working with them will look going forward, given that you still have a stake in that company?

Steve Lisi

Oh, thanks for the question. Justin, look.

XTL was a company looking for an asset, and there were multiple choices for them. I think what excited them about this opportunity is the science.

There's been two landmark papers published about the work done by Dr. Amal, who's the scientist and the innovator behind this approach to treating autism as well as glioblastoma.

It's for people to recognize that the functions of nitric oxide in the brain are numerous. I think that's what attracted them to this.

There's a clear path to human studies. I think a lot of the work that's been done by the neuronOS team has given that clarity to anybody who's taken a look under the hood.

I think it's just a matter of providing the FDA what they require, which is pretty straightforward. It's just a matter of getting that work done.

With XTL coming up with funding, they'll be able to bring this into humans. I think the attractiveness was great science, clear path to human trials, and as everyone on this call probably knows, translating efficacy from rodents to humans is something that's difficult to predict.

We'll find out. I think that's what attracted them.

We're going to get there and do that study and figure out if the efficacy translates. If it does, we're looking at a potential treatment for autism and glioblastoma at this point.

It's very exciting. Just a little bit early for Beyond Air to maintain and fund.

This is why the transaction was done. We're very happy that a lot of this transaction for Beyond Air is us getting a 20% stake in the new entity.

That's the confidence we have that this is going to be in human trials. We have confidence on the safety side, for sure.

The efficacy side, we'll see what happens.

Justin Walsh

Got it. Thanks.

Steve Lisi

Yep.

Operator

The next question is from the line of Jason Kolbert with D. Boral Capital.

Please proceed with your questions.

Jason Kolbert

Good morning, guys. Can we talk a little bit about COGS and how COGS performed in the quarter?

Over the next couple of years, what do you think a sustainable COGS is?

Steve Lisi

Dan, you want to take that one?

Dan Moorhead

Sure. We tend to see Gen 1, again, we think we're in the, and Steve can help me on this, I'm still pretty new on it, but, we expect COGS long-term as we get to scale, in the 60% range and and moving up towards 70 with the Gen 2 product.

In the near-term, again, with with revenue levels growing, but growing at a more moderate pace until we hit the Gen 2 launch, again, I think you're going to see it pretty close to that what you saw in Q3 and continue to grow from there. Long-term, I think that gives you a little profile.

I'm guessing you guys have possibly talked about that in the past as well.

Jason Kolbert

Just to

Steve Lisi

follow up on what Dan said, if you don't mind. I think Dan's right in what he says, but there are a couple of factors, and like Dan said, he's barely two months in.

There are a couple of factors that we're still trying to figure out with respect to the margin on, and that would be from a pricing side of the market. I think that goal of 70% with the Gen 2 is a great goal.

That's target. If it's 65, it's 65, that's not the end of the world for us.

I think that's our target, and I think we'd like to hit it. Target with Gen 1 would be to get close to 60.

Again, I think a Gen 1 is more of a 50s type thing. Again, it's going to depend on how the price shakes out in the market at the end of the day.

That remains to be seen.

Jason Kolbert

Very helpful. Can you talk also about SG&A and how sensitive the sales cycle would be to increasing SG&A, hiring additional sales people?

How does that impact kind of revenues? What I'm trying to do is get a handle on more capital deployed in SG&A, does that translate into more revenues?

Steve Lisi

Jason, you got

Operator

Thank you. The next question is from the line of Yale Jen with Laidlaw.

Please proceed with your questions.

Yale Jen

Good morning, and thanks for taking the questions. Just in the press release, it mentioned that for the Gen 2, it has the potential of extending the service intervals.

Could you elaborate a little bit more on that specific aspect? Hello?

Can you hear me?

Steve Lisi

Hello?

Operator

Hey, your line is live for a question. Please go ahead.

Yale Jen

Yes, I am.

Operator

Thank you.

Yale Jen

Hello, can you hear me?

Operator

Please stand by, ladies and gentlemen. We're experiencing technical difficulties.

Our conference will resume momentarily. Thank you.

Please remain on the line. Our conference will resume momentarily.

Please remain on the line, ladies and gentlemen. Our call will resume momentarily.

Thank you. Steve, you are now reconnected.

Please continue. Caller, please go ahead with your question.

Yale Jen

Sure. Thanks.

Hey, Steve. Thanks for taking the questions.

I believe in the press release, you mentioned that the second-gen will have the potential of extending the service intervals. Could you elaborate a little bit more specifically on this particular aspect?

Then I have a follow-up.

Steve Lisi

Thanks, Yale. Appreciate that question.

The current system, the first-generation system, every 1,000 hours, we need to bring it in for service. That can it could be a slight disruption for the hospital if they're using a couple thousand hours a year per machine, we might be in there every six months rotating machines.

It's a smooth process, but it's an expensive process for us, right? We just come in, drop them a new machine and pick that one up and bring it in for service.

It's not very frequent, but it's something we'd like to improve upon. With the second-generation machine, we think that service interval will be pushed out to at least 3,000 hours and potentially longer.

Testing is still going on. We haven't reached that juncture yet where the reliability testing that we're doing has stopped.

It's still ongoing. We're past the 3,000-hour mark at this point, which means it's at least three times longer before we have to go in.

If we were going in at a hospital, let's say we were going in every 10 months, now we're going in every 30 months on average before we have to swap out the machines. That's it's certainly better for the hospital from that standpoint, although I don't think this swap outs are really a problem for them, because our team does a great job, and it runs so smooth.

From a gross margin perspective, I think that's the impact that you heard about earlier on a question when Dan and I were responding to the gross margins between Gen 1 and Gen 2.

Yale Jen

Okay. Great.

Maybe just touch on this one a little bit, which is would this be needed You mentioned you're still testing for maybe even longer interval for the service needed. Would that be required before you submit for the Gen 2 review?

Or that's something that could be the Gen 2 review without having this particular aspect?

Steve Lisi

No, this is so there is a reliability hurdle with FDA. We've already passed that hurdle.

Anything that we get is just more of a guide for us for service with our customers. That's really what it is.

It's not a gating factor for FDA approval.

Yale Jen

Okay. Great.

Maybe just one more question. On the on the oncology side, that since you guys already have a little bit more cash in hands, should we think about the Phase 2 Phase 1b study potential to start later this calendar year?

Thanks.

Steve Lisi

I don't know when it will start, Yale. We're certainly speaking with people and looking at that.

I don't want to commit to a timeline at this point. While we do have a nice balance sheet at this moment in time, I think we need to focus the balance sheet on the commercial operations at this point.

It would probably not be something that Beyond Air would commit to fully fund a study like that. Maybe once we are more comfortable with our path to profitability, that could be a different conversation that we have internally.

Yale Jen

Okay. Great.

That's very helpful, and congrats on the good quarter in terms of the top line.

Steve Lisi

Great. Thanks, Yale.

Operator

Thank you. At this time, we are showing no further questions in the queue, and this concludes our question-and-answer session.

I would now like to turn the call back over to Steve Lisi for any closing remarks.

Steve Lisi

Now I would just like to thank everybody for dialing in today. Bye-bye.

Operator

Thanks, everyone, for their time today. You may now disconnect your lines at this time, and have a wonderful day.